CD274 and gastric cancer: However, despite this evidence, in the only randomized phase III clinical trial of anti-PD-1 immunotherapy in gastric cancer published so far (ATTRACTION-2), no differences in survival benefit were seen between patients with PD-L1-positive tumors and those with PD-L1-negative tumors 21.